A La Cava

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis
    Veronica De Rosa
    Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, Naples, Italy
    J Clin Invest 116:447-55. 2006
  2. ncbi request reprint Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide
    Francesca Ferrera
    David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Arthritis Rheum 56:1945-53. 2007
  3. doi request reprint Targeting the BLyS-APRIL signaling pathway in SLE
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Clin Immunol 148:322-7. 2013
  4. ncbi request reprint Proinflammatory activities of leptin in non-autoimmune conditions
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Inflamm Allergy Drug Targets 11:298-302. 2012
  5. ncbi request reprint Targeting BLyS in systemic lupus erythematosus
    Yaoyang Liu
    Department of Medicine of the University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Recent Pat Inflamm Allergy Drug Discov 6:91-6. 2012
  6. pmc IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
    Milan Fiala
    Department of Medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, 650 Charles E, Young Dr, South, Los Angeles, CA 90095 1735, USA
    J Neuroinflammation 7:76. 2010
  7. pmc Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis
    Jennifer M P Woo
    Department of Medicine Rheumatology, David Geffen School of Medicine, University of California, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    Arthritis Res Ther 12:R93. 2010
  8. ncbi request reprint Manipulation of immune regulation in systemic lupus erythematosus
    Antonio La Cava
    Division of Rheumatology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA
    Autoimmun Rev 4:515-9. 2005
  9. doi request reprint Lupus and T cells
    A La Cava
    Division of Rheumatology, Department of Medicine, University of California, Los Angeles, California, USA
    Lupus 18:196-201. 2009
  10. pmc Tregs are regulated by cytokines: implications for autoimmunity
    Antonio La Cava
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Autoimmun Rev 8:83-7. 2008

Research Grants

  1. Role of Leptin in Systemic Lupus Erythematosus
    Antonio La Cava; Fiscal Year: 2010
  2. Leptin-based intervention in systemic autoimmunity
    Antonio La Cava; Fiscal Year: 2006
  3. Role of Leptin in Systemic Lupus Erythematosus
    Antonio La Cava; Fiscal Year: 2007

Collaborators

Detail Information

Publications64

  1. pmc Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis
    Veronica De Rosa
    Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, Naples, Italy
    J Clin Invest 116:447-55. 2006
    ..Taken together, our data provide what we believe is a new molecular basis for leptin antagonism in EAE and envision novel strategies of leptin-based molecular targeting in the disease...
  2. ncbi request reprint Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide
    Francesca Ferrera
    David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Arthritis Rheum 56:1945-53. 2007
    ..The purpose of the present study was to test our hypothesis that T cells that recognize an Ig consensus sequence presented by B cells will modulate lupus-like disease in mice...
  3. doi request reprint Targeting the BLyS-APRIL signaling pathway in SLE
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Clin Immunol 148:322-7. 2013
    ..Yet, there is currently a need to both understand better the mechanisms of action of belimumab in SLE and better define the subsets of patients that are more likely to respond to the drug...
  4. ncbi request reprint Proinflammatory activities of leptin in non-autoimmune conditions
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Inflamm Allergy Drug Targets 11:298-302. 2012
    ....
  5. ncbi request reprint Targeting BLyS in systemic lupus erythematosus
    Yaoyang Liu
    Department of Medicine of the University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Recent Pat Inflamm Allergy Drug Discov 6:91-6. 2012
    ..This review provides an overview on the targeting of BLyS in lupus animal models, the use of belimumab in human SLE, and relevant patents...
  6. pmc IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
    Milan Fiala
    Department of Medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, 650 Charles E, Young Dr, South, Los Angeles, CA 90095 1735, USA
    J Neuroinflammation 7:76. 2010
    ..Immune modulation of chronic inflammation may be a new approach to sALS...
  7. pmc Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis
    Jennifer M P Woo
    Department of Medicine Rheumatology, David Geffen School of Medicine, University of California, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    Arthritis Res Ther 12:R93. 2010
    ....
  8. ncbi request reprint Manipulation of immune regulation in systemic lupus erythematosus
    Antonio La Cava
    Division of Rheumatology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA
    Autoimmun Rev 4:515-9. 2005
    ....
  9. doi request reprint Lupus and T cells
    A La Cava
    Division of Rheumatology, Department of Medicine, University of California, Los Angeles, California, USA
    Lupus 18:196-201. 2009
    ....
  10. pmc Tregs are regulated by cytokines: implications for autoimmunity
    Antonio La Cava
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Autoimmun Rev 8:83-7. 2008
    ....
  11. doi request reprint T-regulatory cells in systemic lupus erythematosus
    A La Cava
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1670, USA
    Lupus 17:421-5. 2008
    ..This review provides an update on the role of Tregs in SLE, discussing new findings in relation to possible targeting of Tregs for immune modulation in lupus...
  12. ncbi request reprint CD4+CD25+ Tregs and NKT cells: regulators regulating regulators
    Antonio La Cava
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Trends Immunol 27:322-7. 2006
    ..The advances in our understanding of the interactions between distinct subsets of regulatory T cells in autoimmunity might unveil new methods for harnessing these cells with immunotherapeutic properties...
  13. ncbi request reprint Natural and adaptive immune cell-based therapies in autoimmunity
    Antonio La Cava
    David Geffen School of Medicine, University of California, Los Angeles, California 90095 1670, USA
    Curr Med Chem 13:1557-66. 2006
    ..This review highlights the advances, obstacles and limitations of these studies and critically discusses the most recent findings in this rapidly expanding field...
  14. ncbi request reprint Immunotherapy with peptides in systemic lupus erythematosus
    Antonio La Cava
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1670, USA
    Curr Med Chem 16:1482-8. 2009
    ..This review describes the experimental evidence, rationale, and preclinical models of autoantibody-derived peptide immunotherapy in SLE, and how this information is translating into clinical studies in humans...
  15. ncbi request reprint The weight of leptin in immunity
    Antonio La Cava
    Autoimmunity and Tolerance Laboratory, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Nat Rev Immunol 4:371-9. 2004
    ..Here, we review the advances and controversy for a role of leptin in the pathophysiology of immune responses...
  16. ncbi request reprint Natural Tregs and autoimmunity
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Front Biosci (Landmark Ed) 14:333-43. 2009
    ..This review discusses the role of natural Tregs in the suppression of autoimmune responses and the relevance of these cells for possible therapeutic applications in autoimmunity...
  17. ncbi request reprint The busy life of regulatory T cells in systemic lupus erythematosus
    Antonio La Cava
    Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Discov Med 8:13-7. 2009
    ....
  18. ncbi request reprint Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA
    Antonio La Cava
    Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 173:3542-8. 2004
    ..These findings suggest possible relevance of Ag specificity in the mechanism of T(R)-mediated immune tolerance to Ig-derived peptides in NZB/W F(1) mice...
  19. pmc Targeting B cells with biologics in systemic lupus erythematosus
    Antonio La Cava
    Lupus Research Laboratory, Division of Rheumatology, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Expert Opin Biol Ther 10:1555-61. 2010
    ....
  20. pmc Anticytokine therapies in systemic lupus erythematosus
    Antonio La Cava
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Immunotherapy 2:575-82. 2010
    ..This article provides an overview on antibody-based approaches in SLE that, although preliminary, have the potential to expand the current therapeutic possibilities in the disease...
  21. ncbi request reprint Leptin-based immune intervention: current status and future directions
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Curr Opin Investig Drugs 4:1327-32. 2003
    ..This review presents current preclinical evidence and potential applications for leptin-based immune approaches aimed at improving therapy for chronic and autoimmune conditions...
  22. pmc Modulation of autoimmunity with artificial peptides
    Antonio La Cava
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Autoimmun Rev 10:18-21. 2010
    ..Examples of use of artificial peptides in preclinical studies and in the management of human autoimmune diseases are provided...
  23. pmc Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice
    R Dinesh
    Division of Rheumatology, Department of Medicine at the David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Genes Immun 12:360-9. 2011
    ..Our findings indicate a potential role for Ifi202b in the suppressive capacity of peptide-induced regulatory CD8(+) Ti cells through effects on the expression of Foxp3 and the synthesis of TGFβ...
  24. ncbi request reprint CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression
    Ram Pyare Singh
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 1001 Veteran Avenue, Los Angeles, CA 90095, USA
    J Immunol 178:7649-57. 2007
    ....
  25. ncbi request reprint Genetic immunization maps T cell (auto)immune responses to self antigens homologous to exogenous proteins
    Antonio La Cava
    Department of Medicine, University of California, San Diego, La Jolla 92093 0663, USA
    Autoimmunity 35:105-10. 2002
    ..Furthermore, preferential secretion of Th1-type pro-inflammatory cytokines occurred. This strategy can allow rapid screening of interactive immune networks involving aminoacid sequence homologies between organisms...
  26. doi request reprint Distinct gene signature revealed in white blood cells, CD4(+) and CD8(+) T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide
    R P Singh
    Division of Rheumatology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Genes Immun 11:294-309. 2010
    ..However, silencing of Foxp3 reduced expression of Foxp3, Ifi202b and PD1-all of which are involved in the suppressive capacity of CD8(+) Treg in this model...
  27. doi request reprint Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease
    S D Liu
    University of California, Los Angeles, CA, USA
    Lupus 20:473-84. 2011
    ..Together, the findings highlight galectin-1 as a novel potential therapeutic immune modulator for treatment of lupus-like disease...
  28. doi request reprint Lupus, the current therapeutic approaches
    M Wong
    Division of Rheumatology at the David Geffen School of Medicine, University of California Los Angeles, California, USA
    Drugs Today (Barc) 47:289-302. 2011
    ..In addition, the emerging therapeutic modalities in SLE that use biologics such as monoclonal antibodies to immune cell surface molecules or cytokines, synthetic peptides, oligonucleotides and cell-based therapies are discussed here...
  29. ncbi request reprint Tuning immune suppression in systemic autoimmunity with self-derived peptides
    Ram Pyare Singh
    Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, CA 90095 1670, USA
    Inflamm Allergy Drug Targets 7:253-9. 2008
    ....
  30. ncbi request reprint Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors
    Bevra H Hahn
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 175:7728-37. 2005
    ....
  31. ncbi request reprint Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus
    Noriko Iikuni
    University of California Los Angeles, Division of Rheumatology, Department of Medicine, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Expert Opin Biol Ther 9:201-6. 2009
    ..Some patients may not respond well to some treatments because of inter-individual variability of the disease. More specific and safer therapies are needed...
  32. pmc Cellular and molecular mechanisms of regulation of autoantibody production in lupus
    Bevra H Hahn
    Division of Rheumatology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 91436, USA
    Ann N Y Acad Sci 1051:433-41. 2005
    ..Therefore, strategies described here might ultimately be useful in therapy of the human disease...
  33. ncbi request reprint Mimicking self-antigens with synthetic peptides in systemic autoimmune rheumatic diseases
    Chunlin Cai
    Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Curr Clin Pharmacol 4:142-7. 2009
    ..Preclinical studies in animal models have given encouraging results, and synthetic peptide-based intervention in human autoimmune rheumatic diseases is now approaching translational work into clinical settings...
  34. ncbi request reprint Antibody-based therapies in systemic lupus erythematosus
    Noriko Iikuni
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32 59, Los Angeles, California 90095 1670, USA
    Mini Rev Med Chem 9:829-46. 2009
    ..This review provides an update on the ongoing clinical trials and the promise and obstacles in the use of biologics in SLE...
  35. doi request reprint Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients
    Bevra H Hahn
    Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 58:2488-97. 2008
    ..This study was undertaken to test the possibility that functional human Treg cells can be induced by exposure to anti-DNA Ig-based peptides...
  36. ncbi request reprint Unraveling the multiple roles of leptin in inflammation and autoimmunity
    Antonio La Cava
    Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    J Mol Med (Berl) 82:4-11. 2004
    ..This review focuses on the multiple roles of leptin in chronic inflammation and autoimmunity and suggests new possible therapeutic implications for leptin modulators...
  37. ncbi request reprint pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules
    Ram Pyare Singh
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    J Immunol 180:2069-80. 2008
    ..Our data suggest that tolerization with pCons activates different subsets of inhibitory/cytotoxic CD8+ T cells whose targets are both CD4+CD25- effector T cells and B cells...
  38. pmc Cutaneous vasculitis in breast cancer treated with chemotherapy
    Maida Wong
    Department of Medicine, Division of Rheumatology, University of California Los Angeles, FOCIS Center of Excellence, Los Angeles, CA 90095 1670, USA
    Clin Immunol 129:3-9. 2008
    ....
  39. pmc Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice
    Elaine V Lourenço
    Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    J Immunol 182:7415-21. 2009
    ..Transfer experiments confirmed the role of p38 in Tregs on disease activity in the NZB/W mice. These data indicate that the modulation of p38 activity in lupus Tregs can significantly influence the disease activity...
  40. doi request reprint Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease
    Maida Wong
    Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    J Immunol 185:6563-71. 2010
    ..PD-1 regulation could represent a target to preserve tolerance and prevent autoimmunity...
  41. pmc CD8+ Tregs in lupus, autoimmunity, and beyond
    Ravi K Dinesh
    Division of Rheumatology, Dept of Medicine at the David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Autoimmun Rev 9:560-8. 2010
    ..We also discuss the potential role of CD8(+) Tregs in other diseases, including chronic infection and cancer...
  42. pmc Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus
    Noriko Iikuni
    Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 183:1518-22. 2009
    ..These results indicate that one way by which natural Tregs attempt to limit humoral autoimmunity in SLE is by directly targeting autoreactive B cells...
  43. pmc Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin
    B H Hahn
    Division of Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Lupus 19:913-7. 2010
    ..These data suggest that environmental factors associated with obesity and metabolic syndrome can accelerate atherosclerosis and disease in a lupus-prone background...
  44. pmc Cytokines in systemic lupus erythematosus
    Elaine V Lourenço
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Curr Mol Med 9:242-54. 2009
    ..This review discusses the activity of several cytokines in SLE, their effects on the immune cells in relation to the disease pathogenesis, and the promise and limitations of cytokine-based therapies in clinical trials for lupus patients...
  45. ncbi request reprint Leptin in non-autoimmune inflammation
    Chunlin Cai
    Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1670, USA
    Inflamm Allergy Drug Targets 8:285-91. 2009
    ..This review focuses on the role of leptin in non-autoimmune inflammatory diseases that include renal, liver and lung inflammation, atherosclerosis and metabolic syndrome, Behçet's disease and endometriosis...
  46. ncbi request reprint Leptin as clinical target
    C Cai
    Department of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Recent Pat Inflamm Allergy Drug Discov 3:160-6. 2009
    ..Here, we review the current patents on leptin in different clinic applications...
  47. ncbi request reprint ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia
    Xuebing Feng
    Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, USA
    J Lipid Res 48:794-805. 2007
    ..Correlations of IgG anti-OxPL with lupus-like disease, atherosclerosis, and bone loss suggested a shared pathway of these disease processes...
  48. ncbi request reprint Balancing susceptibility to infection and autoimmunity: a role for leptin?
    Giuseppe Matarese
    Cattedra di Immunologia, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Via S Pansini 5, 80131, Napoli, Italy
    Trends Immunol 23:182-7. 2002
    ....
  49. pmc Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model
    George A Karpouzas
    Rheumatology, Harbor UCLA Medical Center, Torrance, USA
    Eur J Immunol 34:2489-99. 2004
    ..Understanding these defects might identify targets for therapy in systemic lupus erythematosus...
  50. ncbi request reprint The intricate interface between immune system and metabolism
    Giuseppe Matarese
    Institute of Endocrinology Oncology Research, c o Department of Biology and Molecular Cellular Pathology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    Trends Immunol 25:193-200. 2004
    ....
  51. ncbi request reprint Autoreactive T cells mediate NK cell degeneration in autoimmune disease
    Ruolan Liu
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA
    J Immunol 176:5247-54. 2006
    ..Thus, NK cell degeneration may serve as a means evolved by the immune system to control excessive autoimmunity...
  52. ncbi request reprint Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis
    Giuseppe Matarese
    Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Napoli 80131, Italy
    Curr Pharm Des 13:3676-80. 2007
    ....
  53. doi request reprint IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis
    Ruolan Liu
    Department of Neurology, Barrow Neurological Institute, St Joseph s Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA
    Exp Neurol 211:14-24. 2008
    ..These results suggest that a temporal influence of IL-21 on the activity of immunoregulatory circuits can be important in the modulation of the course of the autoimmune disease...
  54. ncbi request reprint Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia
    Ruolan Liu
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ 85013, USA
    J Immunol 175:7898-904. 2005
    ..Induced cooperation of NKT cells and Treg cells may serve as a superior strategy to treat autoimmune disease...
  55. doi request reprint CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity
    Ying Bai
    Institute of Neuroinformatics and Laboratory for Brain and Mind, Dalian University of Technology, Dalian, China
    Eur J Immunol 38:1877-88. 2008
    ..Thus, Th17 cells can promote humoral autoimmunity via a novel mechanism that involves CCL2...
  56. ncbi request reprint A key role of leptin in the control of regulatory T cell proliferation
    Veronica De Rosa
    Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, 80131 Napoli, Italy
    Immunity 26:241-55. 2007
    ..Together with the finding of enhanced proliferation of T(reg) cells observed in leptin- and ObR-deficient mice, these results suggest a potential for therapeutic interventions in immune and autoimmune diseases...
  57. pmc Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells
    Giuseppe Matarese
    Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, 80131 Naples, Italy
    Proc Natl Acad Sci U S A 102:5150-5. 2005
    ..These findings show an inverse relationship between leptin secretion and the frequency of T(Regs) in RRMS and may have implications for the pathogenesis of and therapy for multiple sclerosis...
  58. ncbi request reprint Gene vaccination for the induction of immune tolerance
    Francesca Ferrera
    Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
    Ann N Y Acad Sci 1110:99-111. 2007
    ..We review here the experimental evidence and most recent data supporting the use of DNA vaccination in the induction of immune tolerance...
  59. ncbi request reprint Leptin accelerates autoimmune diabetes in female NOD mice
    Giuseppe Matarese
    Cattedra di Immunologia, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Napoli, Italy
    Diabetes 51:1356-61. 2002
    ..These findings indicate that leptin can favor proinflammatory cell responses and directly influence development of autoimmune disease mediated by Th1 responses...
  60. doi request reprint Regulatory CD4 T cells: sensing the environment
    Giuseppe Matarese
    Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, Italy
    Trends Immunol 29:12-7. 2008
    ....
  61. pmc Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses
    Veronica Sanna
    Gruppo di ImmunoEndocrinologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche IEOS CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Napoli, Italy
    J Clin Invest 111:241-50. 2003
    ..Given that leptin appears to regulate EAE susceptibility, inflammatory anorexia, and pathogenic T-cell immune function, we postulate that it may offer a potential target in the treatment of multiple sclerosis...
  62. ncbi request reprint Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen
    Timothy L Vollmer
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ 85013, USA
    J Immunol 174:2696-701. 2005
    ..Depletion of NK cells abrogated the effect of IL-21. Therefore, IL-21, by affecting NK cells, has differential effects during the initiation and progression of autoimmune responses against neuroantigens...
  63. ncbi request reprint Autoimmunity and celiac disease
    Carmen Gianfrani
    Institute of Food Sciences of CNR, Avellino, Italy
    Mini Rev Med Chem 8:129-34. 2008
    ..We review the most recent studies on CD pathogenesis and the possibilities to modulate immune dysfunction in CD...
  64. ncbi request reprint Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis
    Margherita Massa
    IRCCS Policlinico San Matteo, Pavia, Italy
    Arthritis Rheum 46:3015-25. 2002
    ..The long-term objective of the project is to identify suitable targets for immunotherapy of the disease...

Research Grants6

  1. Role of Leptin in Systemic Lupus Erythematosus
    Antonio La Cava; Fiscal Year: 2010
    ..This study will detail the effects of leptin on human lupus and compare the potential of different leptin-based approaches with the goal to improve the current therapeutic management of human lupus. ..
  2. Leptin-based intervention in systemic autoimmunity
    Antonio La Cava; Fiscal Year: 2006
    ..abstract_text> ..
  3. Role of Leptin in Systemic Lupus Erythematosus
    Antonio La Cava; Fiscal Year: 2007
    ..This study will detail the effects of leptin on human lupus and compare the potential of different leptin-based approaches with the goal to improve the current therapeutic management of human lupus. ..